Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib +/- Atezolizumab in PIK3CA-Mutated Cancers
NCT06496568Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of inavolisib in head and neck squamous cell carcinoma (HNSCC) and PIK3CA-mutant cancer (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Select Treatment-related Toxicities and Percentage of Participants with Adverse Events and Serious Adverse Events. Started Dec 2023; status: active, not recruiting.
02
Drugs
inavolisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)PIK3CA-mutant cancer
Beyond the preview
Go deeper on NCT06496568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496568.